Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

Diabetes Care

Volumn 35, Issue 8, 2012, Pages 1654-1662

  Cavelti Weder, Claudia ^a   Babians Brunner, Andrea ^a   Keller, Cornelia ^a   Stahel, Marc A ^b   Kurz Levin, Malaika ^b   Zayed, Hany ^c   Solinger, Alan M ^c   Mandrup Poulsen, Thomas ^d,e   Dinarello, Charles A ^f   Donath, Marc Y ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c XOMA   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GEVOKIZUMAB; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IMMUNE RESPONSE; INSULIN SENSITIVITY; INSULIN TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS;

EID: 84864386088     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2219     Document Type: Article

References (28)

1. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009;24:325-331
2. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008;31(Suppl. 2):S161-S164
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
4. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110: 851-860
5. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526 (Pubitemid 46588416)
6. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-1668
7. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011;96:2119-2126
8. Donath MY, Mandrup-Poulsen T. The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat Clin Pract Endocrinol Metab 2008;4:240-241 (Pubitemid 351571135)
9. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-3732
10. Roell MK, Issafras H, Bauer RJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 2010;285:20607-20614
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl. 1):S62-S69
12. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470 (Pubitemid 29418240)
13. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production fromnon-CD14+ human blood mononuclear cells. J Clin Invest 1998;101:711-721 (Pubitemid 28084257)
14. Rissanen A, Botha J, Thuren T. IL-1β antibody (canakinumab) improves insulin secretion rates in subjects with impaired glucose tolerance (IGT) and type 2 diabetes (T2DM). Late-breaking abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego Convention Center, San Diego, California
15. Sloan-Lancaster J, Polzer J, Miller JW, Scherer JC, Berg JK, Landschulz WH. Safety, tolerability and efficacy of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Late-breaking abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego Convention Center, San Diego, California
16. Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β- regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 2012;71:563-566
17. Ottenhoff TH, Verreck FA, Lichtenauer- Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002;32:97-105 (Pubitemid 34977203)
18. Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007;12:16-21 (Pubitemid 46763028)
19. Maedler K, Schumann DM, Sauter N, et al. Low concentration of interleukin-1β induces FLICE-inhibitory protein-mediated β-cell proliferation in human pancreatic islets. Diabetes 2006;55:2713-2722 (Pubitemid 44923669)
20. Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 2009;106: 13998-14003
21. Ehses JA, PerrenA, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007;56: 2356-2370 (Pubitemid 47358243)
22. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481-1489
23. Koenen TB, Stienstra R, van Tits LJ, et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1β transcription in human adipose tissue. Diabetes 2011;60: 517-524
24. Stienstra R, Joosten LA, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010;12:593-605
25. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179-188
26. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011;12:408-415
27. Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009;32:2281-2287
28. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162: 597-605